12:16 PM EDT, 08/07/2024 (MT Newswires) -- Bruker ( BRKR ) said Wednesday it has made a minority investment in NovAliX, a France-based contract research organization providing drug discovery services.

Bruker ( BRKR ) said it intends to collaborate with NovAliX on the development of new drug discovery technologies and methods, with the aim of discovering new or improved targets and predicting drug discovery failures earlier.

Bruker ( BRKR ) also said it plans to conduct joint innovation activities with NovAliX through the Biophysics Institute for Biomedical Research, which is set to open in 2026 and host biotechs, startups and academic groups.

Terms of the investment weren't provided.

Price: 61.65, Change: -0.51, Percent Change: -0.83